SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production

Wednesday, February 3, 2010 General News J E 4
AMSTERDAM, February 2 SynCo Bio Partners B.V. todayannounced that it has signed two commercial manufacturing agreements with anundisclosed US biopharmaceutical company. Under the contract, SynCo willprovide both process validation and GMP commercial manufacturing services tosupport the commercial launch of two separate biopharmaceutical products ontothe US market.

SynCo has commenced with preparations for the manufacture of conformancelots in advance of its client's BLA filings, expected in late 2010, inanticipation of commercial manufacturing commencing in 2011.

The products are both recombinant proteins, to be produced in E. coli.These products will be manufactured in SynCo's large-scale GMP facility andtake the tally of marketed products manufactured at its Amsterdam facilitiesto six, since SynCo's inception in 2000. SynCo has previously supportedprocess development efforts for both products; an excellent example of howSynCo supports its clients' biopharmaceutical development programs from earlystage to commercial supply.

Pierre Warffemius, CEO of SynCo Bio Partners said, "This news is afurther example of how SynCo can offer a viable long-term manufacturingchoice to its clients. SynCo has grown steadily over the last ten years in avery competitive market. The foundation of this growth has been our abilityto form strong and mutually beneficial relationships with our clients. As aconsequence, SynCo is one of few biopharmaceutical CMOs in the world with arecognized track record in both clinical and commercial manufacturing,providing financial stability that allows us to continuously invest in ourfacilities."

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and finalproduct CMO with clinical and commercial production experience in mammalianand microbial systems. This experience has been acquired by developing newproduction processes for a number of international clients and producing awide variety of vaccines, recombinant proteins and live bacterial products inour state-of-the-art, GMP-licensed facilities since inception in 2000.

Focused solely on biopharmaceuticals, SynCo acts as a strategic,long-term partner delivering product on time to the highest qualitystandards. SynCo's team is committed to exceeding customer expectations,taking a truly collaborative approach to contract manufacturing.

For more information, please visit

SOURCE SynCo Bio Partners B.V.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Hudson Valley Fertility Establishes Region's First...
February Is Heart Month: These 4 Great Show Ideas ...